Bill Of Health
OCTOBER 17, 2023
Regenerative medical technologies use cell- and tissue-based methods to recapitulate, bioengineer, and reprogram human tissue, making a whole suite of sci-fi-sounding technologies an ever-closer reality. It seems, in the near term, that the “who” would probably be a venture-backed biotechnology company — a corporate actor.
Bill Of Health
SEPTEMBER 13, 2023
These five students are a fantastic cohort of health law policy, biotechnology, and bioethics scholars who join us from Harvard Law School. At the law school, Adithi is interested in examining how emerging biotechnologies in regenerative medicine intersect with patient privacy and other ownership rights.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill Of Health
OCTOBER 27, 2023
The HIPAA Problem The privatization of next-generation medical technologies, especially in regenerative and precision medicine, further muddies the data-protection waters. The innovation-security tradeoff is a familiar trope in biotechnology, but the main character of the direct-to-consumer tissue-based service story is less so.
Bill Of Health
SEPTEMBER 22, 2022
These five students are a fantastic cohort of health law policy, biotechnology, and bioethics scholars who join us from across Harvard. Her research currently focuses on the interplay between intellectual property, transfer of technology, and financing to further access to medical technologies.
Bill Of Health
JANUARY 6, 2022
Failing to do so would be a missed opportunity for the public sector to have a say in the distribution and pricing of this critical medical technology. The NIH, which funded much of Moderna’s research on the COVID-19 vaccine, should be assertive in exerting control over the results of this taxpayer-funded research. The Patent Dispute.
Bill Of Health
SEPTEMBER 16, 2024
2026) research interests include innovative medical technologies and chronic disease policy. Her research interests include genetics, environmental health sciences, novel biotechnologies, and the FDA regulatory process. Rupa Palanki’s (J.D. Department of Health & Human Services and the Louisiana Department of Health.
Bill Of Health
MARCH 23, 2023
Is research in the interest of the public domain an activity exclusively developed by academic or healthcare entities, or can it be carried out by industry (pharmaceutical, biotechnology, technology companies, medical technology industries, and insurance providers)? If so, how?
Expert insights. Personalized for you.
113 
Let's personalize your content